Johnson & Johnson Q4 Profit Decreases

Johnson & Johnson Beats Earnings Estimates and Forecasts 2025 Growth
Johnson & Johnson unveiled financial results that beat Wall Street expectations as the company braces for one of its top-selling medicines, Stelara, to go off patent in the coming weeks.Fourth-quarter sales,
Johnson & Johnson Q4 Profit Decreases, But Beats Estimates
Johnson & Johnson (JNJ) announced a profit for fourth quarter that decreased from last year but beat the Street estimates. The
Johnson & Johnson (JNJ) Q4 2024 Earnings Call Transcript
Operator Good morning and welcome to Johnson & Johnson's fourth quarter 2024 earnings conference call. All participants will be in a listen-only mode until the question-and-answer session of the conference.
Johnson & Johnson Q4 2024 Earnings Preview: Double-digit decline in profit expected
Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q4 earnings results on Wednesday, January 22nd, before market open. Analysts expect a profit per share of $2.02, which is a decline of 11.8% from the prior year period.
Johnson & Johnson stock down despite beat on full-year, Q4 2024 earnings
Johnson & Johnson beat on fourth quarter and full-year 2024 results, but its stock traded down on Wednesday morning to about $143 per share. Several negative impacts were highligh
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago. These figures are adjusted for non-recurring items.
Johnson & Johnson Dips On Q4 Earnings: Here's What The Market Isn't Seeing
Johnson & Johnson's Q4 2024 earnings missed EPS expectations, but broadly met revenue targets. Click here to read why JNJ stock is a Buy.
Johnson Controls buys European building automation tech firm Webeasy
It purchased a developer of software and hardware for controlling and monitoring of technical building installations.
Johnson & Johnson's Spravato nasal spray okayed as stand-alone treatment for depression
Spravato, okayed for stand-alone use among adults, is the first such therapy for major depressive disorder (MDD) that is ...
What Analysts Think of Johnson & Johnson Stock Ahead of Earnings
Johnson & Johnson is set to report earnings before the bell Wednesday, with analysts expecting revenue and profit growth from ...
Johnson Controls shuffles executive roles amid CEO search
Johnson Controls announced July 31, 2024, that CEO Oliver agreed to step down after “constructive dialog” with activist ...
Johnson & Johnson Tops Q4 EPS Forecasts
Johnson & Johnson surpassed earnings expectations with strong sales, but it faces challenges ahead due to patent expirations.
Johnson & Johnson (JNJ) Receives a Hold from Morgan Stanley
In a report released today, Terence Flynn from Morgan Stanley maintained a Hold rating on Johnson & Johnson (JNJ – Research Report), with a ...
Crain's Detroit13d
Cannabis company linked to Johnson bribery scandal enters receivership
Southfield-based PharmaCo Inc. — a cannabis company linked to a bribery scheme to Michigan’s then-top marijuana regulator ...
D Magazine7d
The Dallas Company That Could End an $8 Billion Johnson & Johnson Talc Powder Lawsuit
This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...
NBC Los Angeles3d
Speaker Johnson and 2 GOP senators break with Trump on TikTok extension
In a statement, senators disputed President-elect Donald Trump’s suggestion that he would “most likely” give TikTok a 90-day ...
Morgan Stanley Keeps Their Buy Rating on Johnson Controls (JCI)
Morgan Stanley analyst Christopher Snyder maintained a Buy rating on Johnson Controls (JCI – Research Report) today and set a price target of ...